Results 191 to 200 of about 37,687 (273)

Post‐Omicron cognitive decline is largely reversible: Two‐year multicenter cohort study of domain‐specific outcomes in hospitalized patients

open access: yesNeuroprotection, Volume 4, Issue 3, Page 248-261, September 2026.
Earlier variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), including the original strain, Alpha and Delta, were linked to significant and persistent cognitive impairment. The long‐term cognitive impact of Omicron infection, however, has remained uncertain. This study shows that post‐Omicron cognitive decline is largely reversible,
Min Qiu   +15 more
wiley   +1 more source

Cell‐Type‐Resolved Proteomics Reveals Distinct Immune and Metabolic Programs Between Primary and Recurrent Ascites in HGSOC

open access: yesPROTEOMICS – Clinical Applications, Volume 20, Issue 5, September 2026.
ABSTRACT High‐grade serous ovarian carcinoma (HGSOC) frequently recurs after platinum–taxane therapy, yet recurrence‐associated changes within ascites remain unclear. We performed cell‐type‐resolved quantitative proteomics on paired ascites samples collected at primary diagnosis and at disease recurrence from three HGSOC patients, profiling unsorted ...
Bo Ren   +6 more
wiley   +1 more source

Akkermansia muciniphila and Its Bioactive Derivatives: Emerging Regulators of Healthy Aging

open access: yesAging Cell, Volume 25, Issue 9, September 2026.
The beneficial gut bacterium Akkermansia muciniphila (AKK) declines with age but is enriched in healthy centenarians. Supplementation of AKK extends healthspan and alleviates age‐related decline through direct host–microbe interactions and its bioactive derivatives, which collectively enhance gut barrier integrity, restore metabolic homeostasis ...
Ting Zhang   +7 more
wiley   +1 more source

Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 18, Page 5458-5475, September 2026.
Abstract Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission.
Carlos Núñez‐de la Calle   +12 more
wiley   +1 more source

Pharmacological Modulation of the Kynurenine Pathway Using PF-04859989 Modulates PACAP Signaling in Migraine-Relevant Trigeminal Sensitization. [PDF]

open access: yesBiomolecules
Vágvölgyi-Sümegi E   +9 more
europepmc   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

open access: yesJournal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy